Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Open in API
Filings indexed 830 across all filing types
Latest filing 2019-02-08 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2019-02-08 English
FORM 4
Director's Dealing
2019-02-08 English
SC 13G/A
Major Shareholding Notification
2019-01-17 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 7, 2019. It includes a Regulation FD Disclosure about management meetings reviewing the company's product candidate pipeline and furnishes a presentation as Exhibit 99.1 titled 'Management Presentation'. The document explicitly states that the presentation is furnished and not filed, indicating it is an investor presentation rather than a full financial report. The length is 3420 characters, which is relatively short and consistent with a report furnishing a presentation rather than a full report. Therefore, the document is best classified as an Investor Presentation (IP).
2019-01-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 19, 2018. It provides a corporate update on the partnering process for clinical development candidates and includes a press release as an exhibit. The text explicitly states that the press release is furnished as an exhibit and that the information is not "filed" for purposes of Section 18 of the Exchange Act, indicating this is an announcement rather than a full report. The document length is 3525 characters, which is relatively short and consistent with a regulatory announcement rather than a detailed financial report. There are no financial statements or substantive financial data included, only a corporate update and a press release. Therefore, this document fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2018-12-19 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 6, 2018. It includes a Regulation FD Disclosure about a live presentation by the CEO regarding the company's product pipeline and clinical candidates. The document states that a copy of the presentation is furnished as Exhibit 99.1 titled 'Management Presentation'. The text explicitly mentions that the presentation is furnished as an exhibit and is not filed as part of the report, indicating this document is primarily an announcement of a presentation rather than the presentation itself. The length is 4079 characters, which is relatively short and consistent with an announcement rather than a full report. The content fits best with an Investor Presentation (IP) category, as it focuses on a management presentation to investors about products and pipeline. Therefore, the filing type is Investor Presentation (IP).
2018-12-06 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.